Turn Therapeutics Inc. Common Stock TTRX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | ||
|---|---|---|---|---|
| $365.75K— | $265.57K— | $240.4K— | ||
| $6.35M— | $5.59M— | $3.75M— | ||
| $6.72M— | $5.86M— | $3.99M— | ||
| -$6.72M— | -$5.86M— | -$3.99M— | ||
| $2.88M— | $2.66M— | $197.76K— | ||
| —— | —— | —— | ||
| —— | —— | —— | ||
| -$6.72M— | -$5.86M— | -$3.99M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Turn Therapeutics Inc. Common Stock profitable?
- Turn Therapeutics Inc. Common Stock is not currently profitable: it reported a net loss of $3.5M over the trailing twelve months.
- What is Turn Therapeutics Inc. Common Stock's earnings per share?
- Turn Therapeutics Inc. Common Stock's diluted EPS over the trailing twelve months is $-0.13.
- Where does Turn Therapeutics Inc. Common Stock's income statement data come from?
- Every line is extracted from Turn Therapeutics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.